PINE BROOK, New Jersey, February 13, 2019 /PRNewswire/ --
Global pharmaceutical company, Alvogen, today announced the launch of the first generic equivalent of Revlimid(TM) (lenalidomide) in a range of its operating CEE markets including Romania, Croatia, Bulgaria and the Baltic states. This product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules. Following the launch into CEE region, the generic and bioequivivalent version of Revlimid(TM) will be launched globally in 2019, having been developed in-house at Alvogen's subsidary, Lotus Pharmaceuticals.
(Logo: https://mma.prnewswire.com/media/821412/Alvogen_Logo.jpg )
Hacho Hathcikian, Executive Vice President at Alvogen in the CEE regions, said: "Lenalidomide launch is a major landmark for Alvogen in the CEE region as we successfully become the first generic pharmaceutical company to launch the generic of Revlimid(TM) in our major markets. Patients now finally have access to an affordable and high-quality treatment for the various oncology indications the product is targeted at. Having Lenalidomide in our portfolio also enhances our drive to be one of the key oncology players in the CEE region."
Revlimid(TM) is indicated for the treatment of various oncology diseases including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. By the time of Alvogen launch, Revlimid(TM) is perceived as the single biggest-selling oncology drug with approximately $9.8 billion sales globally.
Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter medicines (OTC) and biosimilar products for patients around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.
Learn more about Alvogen on http://www.alvogen.com
Global Corporate Marketing & Communications
Tel: (+354) 522 2900